Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis

Lenalidomide, with or without prednisone, is an active therapy for patients with myelofibrosis (MF). We provide an update of a phase II study of lenalidomide plus prednisone in patients with MF, after median follow up of 9 years. Forty patients were enrolled in the study and all patients were evalua...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Leuk Res
Hlavní autoři: Chihara, Dai, Masarova, Lucia, Newberry, Kate J., Maeng, Hoyoung, Ravandi, Farhad, Garcia-Manero, Guillermo, Ferrajoli, Alessandra, Cortes, Jorge, Kantarjian, Hagop, Verstovsek, Srdan
Médium: Artigo
Jazyk:Inglês
Vydáno: 2016
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5407688/
https://ncbi.nlm.nih.gov/pubmed/27416326
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2016.06.007
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky